Drug intelligence / Profile preview

GSK2189241A

Development stage: Phase 1
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GSK2189241A is an investigational vaccine developed as a candidate formulation for pneumococcal vaccination, primarily targeting the prevention of pneumococcal disease. It is being evaluated for its immunogenicity and safety in elderly populations. The mechanism of action is through vaccination, stimulating an immune response against *Streptococcus pneumoniae*.

Other names: GSK-2189241AGSK2189241AGSK 2189241A

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on GSK2189241A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2189241A.

Explore the full profile